~~<i id='A433CF032C'><strike id='A433CF032C'><tt id='A433CF032C'><pre id='A433CF032C'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：focus 2025-10-06 07:22:52 Page View：83

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Attacks on the drug industry will lead to fewer breakthroughs
Next article： Tori Bowie and the unacceptable rates of Black maternal death

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

4:01FormerPresidentDonaldTrumpwavesashestepsoffhisplaneatRonaldReaganWashingtonNationalAirport,Aug.3

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

In early work, researchers turn to CRISPR to treat Alzheimer's

AdobeWhenthegenome-editingtoolCRISPRisthoughtofasapotentialmedicine,thetargetsthatfirstcometomindare